Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes

Autor: John N Harvey, Keith Bowering, J. W. Snyder, Bruce W. Bode, J. W. Kolaczynski
Rok vydání: 2018
Předmět:
Blood Glucose
Male
medicine.medical_specialty
endocrine system diseases
Endocrinology
Diabetes and Metabolism
030209 endocrinology & metabolism
Type 2 diabetes
Drug Administration Schedule
law.invention
Insulin aspart
03 medical and health sciences
0302 clinical medicine
Endocrinology
Randomized controlled trial
Double-Blind Method
law
Diabetes mellitus
Internal medicine
Post-hoc analysis
Internal Medicine
medicine
Humans
030212 general & internal medicine
Meals
Insulin Aspart
Research Articles
Aged
Glycated Hemoglobin
business.industry
nutritional and metabolic diseases
Middle Aged
medicine.disease
Postprandial Period
Metformin
Treatment
Regimen
Postprandial
Diabetes Mellitus
Type 2
Short Report: Treatment
Delayed-Action Preparations
Hyperglycemia
Female
business
hormones
hormone substitutes
and hormone antagonists
medicine.drug
Zdroj: Diabetic Medicine
ISSN: 1464-5491
Popis: Aim This post hoc analysis explored whether mealtime fast‐acting insulin aspart treatment provided an advantage in postprandial plasma glucose (PPG) control vs. insulin aspart in people with Type 2 diabetes receiving high doses of bolus insulin. Methods A post hoc, post‐randomization, subgroup analysis of a 26‐week, randomized, double‐blind, treat‐to‐target trial (onset 2) that compared mealtime fast‐acting insulin aspart vs. mealtime insulin aspart, both in a basal–bolus regimen, in people with Type 2 diabetes uncontrolled on basal insulin therapy and metformin. At the end of trial, the impact of fast‐acting insulin aspart and insulin aspart on PPG control was assessed with a standard liquid meal test and participants were grouped into three post‐randomization subgroups: meal test bolus insulin dose ≤ 10 units per dose (n = 171), > 10–20 units per dose (n = 289) and > 20 units per dose (n = 146). Results A statistically significant treatment difference in favour of fast‐acting insulin aspart vs. insulin aspart was observed for the change in PPG increment at all post‐meal time points (from 1 to 4 h) for those in the > 20 units bolus insulin subgroup. There was no difference in the magnitude of change from baseline in HbA1c level between fast‐acting insulin aspart and insulin aspart in any of the bolus insulin dose subgroups (data herein). Conclusion Fast‐acting insulin aspart may hold promise as a more effective treatment compared with insulin aspart for controlling PPG in people with insulin‐resistant Type 2 diabetes.
What's new? The results of this post hoc analysis indicate that fast‐acting insulin aspart may provide an advantage over conventional rapid‐acting insulin analogues in controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes requiring basal–bolus therapy.
Databáze: OpenAIRE
Externí odkaz: